Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India

Mycoses

Volumn 59, Issue 2, 2016, Pages 93-100

  Mane, Arati ^a   Vidhate, Pallavi ^a   Kusro, Chanchal ^a   Waman, Vaishali ^b   Saxena, Vandana ^a   Kulkarni Kale, Urmila ^b   Risbud, Arun ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF PUNE   (India)

Author keywords

Candida albicans; Drug efflux; ERG11 mutations; Fluconazole resistance

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; ABC TRANSPORTER; ANTIFUNGAL AGENT; CARRIER PROTEIN; CDR1 PROTEIN, CANDIDA ALBICANS; CYTOCHROME P-450 CYP51, CANDIDA ALBICANS; CYTOCHROME P450; FUNGAL DNA; FUNGAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CROSS RESISTANCE; DNA SEQUENCE; FUNGUS ISOLATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; INDIA; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; CANDIDIASIS; DRUG EFFECTS; FUNGAL GENE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MOLECULAR GENETICS;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; CANDIDIASIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENES, FUNGAL; HUMANS; INDIA; MEMBRANE TRANSPORT PROTEINS; MOLECULAR SEQUENCE DATA; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84954026753     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12439     Document Type: Article

References (37)

1. Kim J, Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol 2011; 49: 171-7.
2. Morio F, Loge C, Besse B, Hennequin C, Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 2010; 66: 373-84.
3. Xiang MJ, Liu JY, Ni PH et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 2013; 13: 386-93.
4. Goldman G, Ferreira M, Marques E et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004; 50: 25-32.
5. Sanglard D, Odds F. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
6. Loeffler J, David S. Antifungal Drug Resistance. Clin Infect Dis 2003; 36: S31-41.
7. Zhang L, Yang HF, Liu YY, Xu XH, Ye Y, Li JB. Reduced susceptibility of Candida albicans clinical isolates to azoles and detection of mutations in the ERG11 gene. Diagn Microbiol Infect Dis 2013; 77: 327-9.
8. Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 27: 403-8.
9. Park S, Perlin D. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005; 11: 232-8.
10. Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-8.
11. Flowers SA, Barker KS, Berkow EL et al. Gain-of-function mutations in UPC2Are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 2012; 11: 1289-99.
12. Perea S, Lopez-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-84.
13. Mane A, Panchvalli S, Bembalkar S, Risbud A. Species distribution & antifungal susceptibility of oral Candida colonising or infecting HIV infected individuals. Indian J Med Res 2010; 131: 836-8.
14. Oberoi J, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res 2012; 136: 997-1003.
15. Rathod V, Raut J, Karuppayil M. In vitro antifungal susceptibility reveals occurrence of azole resistance among clinical isolates of Candida albicans. Asian J Pharm Clin Res 2012; 5: 170-3.
16. Saranya S, Moorthy K, Malar S et al. Prevalence and antifungal susceptibility pattern of Candida albicans from low socio-economic group. Int J Pharm Sci 2014; 6: 158-62.
17. Mane A, Gaikwad S, Bembalkar S, Risbud A. Increased expression of virulence attributes in oral Candida albicans isolates from HIV -positive individuals. J Med Microbiol 2012; 61: 285-90.
18. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard M27-A2, 2nd edn. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
19. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2002; 46: 1781-4.
20. Priscilla LS, Milan EP, Martinez R, Telles FQ, Ferreira MS, Alcântara AL. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz 2002; 98: 253-7.
21. Martel C, Parker J, Bader O et al. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob Agents Chemother 2010; 54: 4527-33.
22. Kolaskar AS, Kulkarni-Kale U. Prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus. Virology 1999; 261: 31-42.
23. Kulkarni-Kale U, Ojha J, Manjari GS et al. Mapping antigenic diversity and strain specificity of mumps virus: a bioinformatics approach. Virology 2007; 359: 436-46.
24. Sagatova AA, Keniya MV, Wilson RK, Monk BC, Tyndall JD. Structural insights into binding of the antifungal drug fluconazole to Saccharomyces cerevisiae lanosterol 14α-demethylase. Antimicrob Agents Chemother 2015; 59: 4982-9. doi:10.1128/AAC.00925-15.
25. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 34: 779-815.
26. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000; 9: 1753-73.
27. Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins 1993; 17: 355-62.
28. Laskowski RA, Hutchinson EG, Michie AD, Wallace AC, Jones ML, Thornton JM. PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci 1997; 22: 488-90.
29. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-13.
30. Lee M, Williams L, Warnock D, Beth A. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-24.
31. Flowers SA, Colon B, Whaley SG, Schuler MA, Rogers PD. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 2015; 59: 450-60.
32. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 1999; 262: 174-9.
33. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76-81.
34. Zhang JY, Liu JH, Liu FD et al. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses 2014; 57: 584-91.
35. Coste A, Turner V, Ischer F et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006; 172: 2139-56.
36. Lohberger A, Coste AT, Sanglard D. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryot Cell 2014; 13: 127-42.
37. Lyons CN, White TC. Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother 2000; 44: 2296-303.